BioTelemetry Inc.
Find Ratings Reports
-0.22 |
-0.49%
BIOTELEMETRY INC's gross profit margin for the first quarter of its fiscal year 2018 has increased when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its industry. BIOTELEMETRY INC has strong liquidity. Currently, the Quick Ratio is 1.66 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 80.78% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
| Income Statement | Q1 FY18 | Q1 FY17 |
|---|---|---|
| Net Sales ($mil) | 94.5 | 55.88 |
| EBITDA ($mil) | 21.65 | 9.32 |
| EBIT ($mil) | 11.82 | 5.6 |
| Net Income ($mil) | 5.98 | 0.2 |
| Balance Sheet | Q1 FY18 | Q1 FY17 |
|---|---|---|
| Cash & Equiv. ($mil) | 36.35 | 25.1 |
| Total Assets ($mil) | 528.03 | 204.58 |
| Total Debt ($mil) | 203.7 | 25.13 |
| Equity ($mil) | 258.35 | 142.91 |
| Profitability | Q1 FY18 | Q1 FY17 |
|---|---|---|
| Gross Profit Margin | 67.26 | 63.76 |
| EBITDA Margin | 22.9 | 16.66 |
| Operating Margin | 12.51 | 10.02 |
| Sales Turnover | 0.62 | 1.05 |
| Return on Assets | -1.92 | 24.21 |
| Return on Equity | -3.93 | 34.66 |
| Debt | Q1 FY18 | Q1 FY17 |
|---|---|---|
| Current Ratio | 1.96 | 1.89 |
| Debt/Capital | 0.44 | 0.15 |
| Interest Expense | 1.89 | 0.39 |
| Interest Coverage | 6.25 | 14.43 |
| Share Data | Q1 FY18 | Q1 FY17 |
|---|---|---|
| Shares outstanding (mil) | 32.79 | 28.63 |
| Div / share | 0.0 | 0.0 |
| EPS | 0.17 | 0.01 |
| Book value / share | 7.88 | 4.99 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 344983.0 | 458832.0 |
BUY. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 5.69 indicates a significant premium versus the S&P 500 average of 3.29 and a significant premium versus the industry average of 3.56. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, BIOTELEMETRY INC seems to be trading at a premium to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAT NM | Peers 44.23 | BEAT 52.90 | Peers 14.44 | |||||||||||||||||||||
|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. BEAT's P/E is negative making this valuation measure meaningless. |
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. BEAT is trading at a significant premium to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| BEAT 29.91 | Peers 16.47 | BEAT NA | Peers 0.90 | |||||||||||||||||||||
|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. BEAT is trading at a significant premium to its peers. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| BEAT 5.69 | Peers 3.56 | BEAT -120.49 | Peers 52.01 | |||||||||||||||||||||
|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. BEAT is trading at a significant premium to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, BEAT is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| BEAT 4.52 | Peers 0.98 | BEAT 50.94 | Peers 6.28 | |||||||||||||||||||||
|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. BEAT is trading at a significant premium to its industry. |
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share. BEAT has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
